Welcome to our dedicated page for Evogene Ltd. SEC filings (Ticker: EVGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Evogene Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Evogene Ltd.'s regulatory disclosures and financial reporting.
Armistice Capital, LLC and Steven Boyd report their ownership of Evogene Ltd. ordinary shares on an amended Schedule 13G. They report beneficial ownership of 713,539 shares, representing 4.99% of the class.
The shares are held directly by Armistice Capital Master Fund Ltd., for which Armistice Capital serves as investment manager with voting and investment power under an Investment Management Agreement. Steven Boyd, as managing member of Armistice Capital, may also be deemed to beneficially own these securities. All reported voting and dispositive powers are shared, with no sole voting or dispositive power reported. The Master Fund has the right to receive dividends and sale proceeds from the securities.
Evogene Ltd. shareholders led by L.I.A. Pure Capital Ltd. and Invest Pro Shukai Hon Ltd. report increased ownership following open-market purchases of 533,088 American Depositary Shares (ADSs) by Pure Capital using working capital.
After these transactions, the reporting persons collectively report beneficial ownership of 3,057,488 Ordinary Share equivalents, representing 19.35% of Evogene’s outstanding share capital, based on 15,801,407 Ordinary Shares outstanding as of July 27, 2026. Pure Capital has sole dispositive power over 2,501,388 ADSs and 56,100 Ordinary Shares (about 16.19% of the company), while Invest Pro has sole dispositive power over 500,000 ADSs (about 3.16%). Voting power over 3,001,388 ADSs and 56,100 Ordinary Shares is shared under an oral voting agreement. Kfir Silberman and Ron Yair Peled may be deemed beneficial owners through their control of Pure Capital and Invest Pro, respectively, but each disclaims beneficial ownership beyond their pecuniary interest.
Evogene Ltd. director Leon Recanati reports updated beneficial ownership of the company’s ordinary shares. As of this amendment, he beneficially owns 1,354,836 Ordinary Shares, representing 8.6% of Evogene’s outstanding Ordinary Shares, based on 15,801,407 shares outstanding as of July 27, 2026. This total includes 1,343,886 shares held directly and 10,950 shares underlying options that are currently exercisable or exercisable within 60 days of August 11, 2026.
On August 11, 2026, Recanati purchased an additional 460,000 Ordinary Shares in open market transactions at a price of $0.635 per share, for aggregate consideration of $292,100, funded with his personal funds. He has sole voting and dispositive power over all shares he beneficially owns and reports no agreements with others regarding Evogene securities.
Evogene Ltd. director Leon Recanati reported purchasing 460,000 Ordinary Shares on August 11, 2026 at $0.635 per share in an open-market or private transaction. Following this trade, he directly holds 1,343,886 Ordinary Shares. The filing also lists several existing stock option awards over Ordinary Shares at exercise prices ranging from $1.29 to $54.32 with expirations between 2027 and 2035; per the footnotes, these option rows reflect holdings only and no new transactions.
Evogene Ltd. investor and director Leon Recanati filed a Schedule 13D reporting beneficial ownership of 894,836 ordinary shares, or 5.7% of Evogene’s outstanding ordinary shares. This includes 883,886 shares held directly and 10,950 shares underlying options that are currently exercisable or exercisable within 60 days of August 4, 2026.
On August 4, 2026, he purchased 800,000 ordinary shares in open-market transactions at a weighted average price of $0.50 per share, for aggregate consideration of approximately $400,000, using personal funds. Recanati states he acquired the shares for investment purposes and, as a director, intends to vote all shares he beneficially owns in favor of the slate of director nominees put forward by Evogene’s current board at the 2026 annual general meeting, which includes a contested director election. He indicates he may buy or sell additional Evogene securities in the future depending on conditions.
An investor group associated with L.I.A. Pure Capital Ltd., Invest Pro Shukai Hon Ltd., Kfir Silberman and Ron Yair Peled reported an increased stake in Evogene Ltd. Following open-market purchases between August 3 and August 6, 2026, Pure Capital acquired 216,300 additional American Depositary Shares (ADSs) using working capital.
Based on 15,801,407 Ordinary Shares outstanding as of July 27, 2026, the group now reports beneficial ownership of 2,524,400 shares, representing approximately 15.98% of Evogene’s outstanding share capital. Pure Capital has sole dispositive power over 1,968,300 ADSs and 56,100 Ordinary Shares, or about 12.81%, while Invest Pro has sole dispositive power over 500,000 ADSs, or about 3.16%. Voting power over 2,468,300 ADSs and 56,100 Ordinary Shares is shared under an oral voting agreement.
Evogene Ltd. director Leon Recanati purchased 800,000 Ordinary Shares on August 4, 2026 in multiple transactions at a weighted average price of $0.50 per share, increasing his direct ownership to 883,886 Ordinary Shares. He also reports existing stock option positions for informational purposes.
Evogene Ltd. has called its 2026 annual general meeting for 12:00 p.m. (Israel time) on September 4, 2026, with a record date of August 11, 2026. Shareholders must choose between the incumbent seven-member Evogene Slate and a four-member Pure Capital Slate for the board, and may cast a vote only “FOR” one slate.
Other proposals seek to increase authorized share capital from NIS 6,000,000 (30,000,000 ordinary shares) to NIS 30,000,000 (150,000,000 ordinary shares), approve a framework for a reverse share split between 1-for-2 and 1-for-15 to help satisfy Nasdaq’s $1.00 minimum bid requirement, and reappoint Kost Forer Gabbay & Kasierer as independent auditors.
The board cites prior restructuring, lower expected annual cash burn and asset divestiture proceeds as support for its strategy and recommends voting for the Evogene Slate and all other proposals. Ms. Olga Nissan has stepped down as VP Business Development effective July 31, 2026.
Evogene Ltd. shareholders L.I.A. Pure Capital Ltd., Invest Pro Shukai Hon Ltd., Kfir Silberman and Ron Yair Peled report updated holdings and actions in Amendment No. 2 to their Schedule 13D. Together they report shared voting power over 2,252,000 ADSs and 56,100 Ordinary Shares, or about 17.41% of Evogene’s share capital, based on at least 13,258,521 Ordinary Shares held by non-affiliates as of July 17, 2026; the actual percentage may be lower if more shares are outstanding.
They report that Pure Capital acquired an additional 80,000 ADSs using working capital in open‑market transactions. They also describe a July 26, 2026 email to Evogene reiterating their demand to convene a special general meeting of shareholders, rejecting certain settlement proposals, reaffirming intentions outlined in a prior demand letter, requesting draft meeting and proxy materials, and reserving all legal rights.
L.I.A. Pure Capital Ltd., Invest Pro Shukai Hon Ltd. and related individuals filed Amendment No. 1 to their Schedule 13D on Evogene Ltd. after Pure Capital purchased 202,000 additional American Depositary Shares (ADSs) using working capital. The reporting persons now beneficially own 2,228,100 Ordinary Shares/ADSs, representing about 16.81% of Evogene’s share capital.
This percentage is calculated using 13,258,521 Ordinary Shares reported as held by non-affiliates as of July 17, 2026, and they state the actual percentage ownership may be lower. Pure Capital has sole dispositive power over 1,672,000 ADSs and 56,100 Ordinary Shares, while Invest Pro has sole dispositive power over 500,000 ADSs, with voting power shared under an oral voting agreement. The individuals may be deemed beneficial owners through their control of these entities but expressly disclaim beneficial ownership beyond their pecuniary interests and the existence of any Section 13(d) group.